You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DA-EPOCH-R

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)

Completed
Has Results
  • Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Campath
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022

Richter Syndrome Trial in United States (Venetoclax, DA-EPOCH-R, R-CHOP)

Recruiting
  • Richter Syndrome
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

DLBCL, High Grade B-Cell Lymphoma Trial in United States (Venetoclax, Rituximab, Etoposide)

Completed
  • Diffuse Large B-Cell Lymphoma
  • High Grade B-Cell Lymphoma
  • Boston, Massachusetts
  • +5 more
Aug 23, 2022

B-cell Lymphoma, Burkitt Lymphoma Trial in Milwaukee (Etoposide, Doxorubicin, Cyclophosphamide)

Not yet recruiting
  • B-cell Lymphoma
  • Burkitt Lymphoma
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Jun 11, 2022

Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
Mar 23, 2022

T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma Trial run

Completed
Has Results
  • T-Cell Peripheral Lymphoma
  • +3 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 28, 2021

High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,

Recruiting
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • +4 more
  • Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
  • R-CHOP; R-DA-EPOCH; R-HD MTX
  • Jinan, Shandong, China
    Department of Hematology, Shandong Provincial Hospital
Dec 7, 2021

Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

Not yet recruiting
  • Double-Expressor Lymphoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Bone Marrow Aspiration and Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)

Not yet recruiting
  • T Cell Lymphoma
  • New Haven, Connecticut
    Yale Smilow Cancer Hospital
Aug 14, 2023

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified,

Recruiting
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
  • +4 more
  • Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
  • Jinan, Shandong, China
    Shandong Provincial Hospital
Nov 18, 2021

Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, DLBCL

Active, not recruiting
Has Results
  • Adult Burkitt Lymphoma
  • +4 more
  • Chicago, Illinois
  • +4 more
Feb 17, 2022

Lymphoma, Mantle Cell, Mantle Cell Lymphoma Trial run by the NCI (Rituximab (R), EPOCH, Bortezomib (B))

Active, not recruiting
Has Results
  • Lymphoma, Mantle Cell
  • Mantle Cell Lymphoma
  • Rituximab (R)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 21, 2021

Healthy Trial in Soeul (DA-5216, DA-5216-R)

Not yet recruiting
  • Healthy
  • Soeul, Korea, Republic of
    Seoul National University Hospital
Aug 16, 2022

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +71 more
  • Chicago, Illinois
  • +5 more
Oct 8, 2021

Mantle Cell Lymphoma, Lymphoma, Mantle Cell Trial run by the NCI (EPOCH-R, GM-CSF, Idiotype vaccine)

Completed
Has Results
  • Mantle Cell Lymphoma
  • Lymphoma, Mantle Cell
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jan 4, 2023

Healthy Trial in Seoul (DA-5215 Tab, DA-5215-R Tab)

Not yet recruiting
  • Healthy
  • DA-5215 Tab
  • DA-5215-R Tab
  • Seoul, Korea, Republic of
    H Plus Yangji Hospital
May 11, 2022

Hepatitis B Trial in Seoul (DA-2803, DA-2803-R, Placebo of DA-2803)

Recruiting
  • Hepatitis B
  • Seoul, Korea, Republic of
    The Catholic University of Korea, Seoul
Jul 14, 2023

Healthy Trial in Seoul (DA-5218, DA-5218-R1 + DA-5218-R2 + DA-5218-R3)

Not yet recruiting
  • Healthy
  • DA-5218
  • DA-5218-R1 + DA-5218-R2 + DA-5218-R3
  • Seoul, Korea, Republic of
    Bumin Hospital
Jul 4, 2022

Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma Trial run by the NCI (Interferon, Rituxan and

Recruiting
  • Lymphomatoid Granulomatosis
  • +3 more
  • Interferon
  • Rituxan and EPOCH
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma Trial in United States (EPOCH-R,

Active, not recruiting
Has Results
  • Burkitt Lymphoma
  • +2 more
  • La Jolla, California
  • +29 more
Nov 2, 2021

Healthy Trial in Seoul (DA-5211, DA-5211-R1 + DA-5211-R2)

Completed
  • Healthy
  • Seoul, Korea, Republic of
    Bumin Hospital
Jun 2, 2022

Functional Dyspepsia Trial in Iksan (DA-5212, DA-5212-R)

Not yet recruiting
  • Functional Dyspepsia
  • Iksan, Muwangro 895, Korea, Republic of
    Wonkwang University Hospital
Apr 24, 2023

Healthy Trial in Gyeonggi-do (DA-2811, DA-2811-R)

Completed
  • Healthy
  • Gyeonggi-do, Seongnam-si, Korea, Republic of
    Seoul National University Bundang Hospital
Jun 2, 2022